Webinar
Discussion of zanubrutinib (BRUKINSA®) for Adult Patients with CLL/SLL
Date: October 31, 2025 | 2:00 PM
Presenters: Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC | Minnesota Oncology
For patients who can’t tolerate ibrutinib or acalabrutinib, what’s next?
Kirollos Hanna takes a practical look at where zanubrutinib fits in the evolving treatment of CLL and SLL. He’ll share insights from Study 215, including how patients previously intolerant to other BTK inhibitors responded, and review updated safety comparisons between zanubrutinib and acalabrutinib.
Key Learnings:
- How to interpret new efficacy and safety data in context of real-world patient management
- What clinicians should know about dosing adjustments and AE prevention
- Practical strategies for managing hypertension, bleeding, and cardiac risk during treatment
For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.